Global Autoimmune Monoclonal Antibody Market Size and Forecast to 2029: Revenue, Growth, and Trends

Uncover key drivers, emerging technologies, and competitive movements shaping the autoimmune monoclonal antibody market from 2025–2034 with trusted insights from The Business Research Company

How Big Is The Autoimmune Monoclonal Antibody Market Size Today And What Will Its Value Be At The End Of 2029?

The autoimmune monoclonal antibody market has experienced robust expansion in recent years. This market is projected to grow from $65.83 billion in 2024 to $70.86 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.6%. The historical growth of this market can be linked to the increasing occurrence of autoimmune diseases, the wider adoption of biologics for treatment, heightened awareness of targeted therapies, the timely approvals of monoclonal antibody medications, and improved healthcare accessibility in developed nations.

The autoimmune monoclonal antibody market size is anticipated to experience robust expansion over the forthcoming years. It is projected to ascend to $96.74 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.1%. This projected growth throughout the forecast period stems from factors such as increasing demand for personalized medicine, rising adoption of biosimilars, expanding clinical trials in autoimmune therapy, a growing geriatric population, and the rising prevalence of chronic immune disorders. Significant developments expected in the forecast period include advancements in antibody engineering, the evolution of bispecific antibodies, the increasing utilization of artificial intelligence in drug discovery, the integration of genomics into treatment planning, and the introduction of novel drug delivery systems.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24162&type=smp

Which Key Drivers Are Powering Growth In The Autoimmune Monoclonal Antibody Market?

The rising need for biologics is anticipated to stimulate the expansion of the autoimmune monoclonal antibody market in the future. Biologics are defined as medical products originating from living organisms or their constituent parts, employed in disease treatment, prevention, or diagnosis. The growing appetite for biologics stems mainly from their efficacy in addressing intricate ailments like cancer, autoimmune disorders, and genetic conditions, often when conventional treatments fall short. Autoimmune monoclonal antibody improves biologic treatments by offering precise immune regulation, rendering them potent for controlling excessive immune reactions. These antibodies decrease the reliance on widespread immunosuppressants through targeted therapy, leading to better patient results and fewer adverse effects. An example illustrates this: in June 2024, data from Cardinal Health Inc., a US-based healthcare company, indicated that 40 Food and Drug Administration (FDA) approved biosimilar products existed in 2023, with 25 of these being commercially accessible in the US market, an uptick from 33 biosimilar products in 2022. Consequently, the heightened demand for biologics is propelling the expansion of the autoimmune monoclonal antibody market.

Which Segment Categories Are Driving Maximum Growth In The Autoimmune Monoclonal Antibody Market?

The autoimmune monoclonal antibody market covered in this report is segmented –

1) By Type: Immunoglobulin G Monoclonal Antibodies, Immunoglobulin M Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Route Of Administration: Subcutaneous, Intravenous, Intramuscular

3) By Application: Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosus, Psoriasis, Inflammatory Bowel Disease

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Outpatient Clinics, Homecare Settings, Research Institutions

Subsegments:

1) By Immunoglobulin G (IgG) Monoclonal Antibodies: Immunoglobulin G1 (IgG1), Immunoglobulin G2 (IgG2), Immunoglobulin G3 (IgG3), Immunoglobulin G4 (IgG4)

2) By Immunoglobulin M (IgM) Monoclonal Antibodies: Pentameric Immunoglobulin M (IgM), Hexameric Immunoglobulin M (IgM)

3) By Chimeric Monoclonal Antibodies: Murine Variable Region + Human Constant Region, Humanized Variable Region + Murine Constant Region

4) By Fully Human Monoclonal Antibodies: Phage Display-Derived, Transgenic Mouse-Derived, Fully Human Hybridoma-Derived

What Key Trends Are Driving Growth In The Autoimmune Monoclonal Antibody Market?

Leading companies in the autoimmune monoclonal antibody field are concentrating on developing innovative solutions, such as biosimilar development, to enhance their safety, efficacy, and quality. Biosimilar development constitutes the creation of biological products that are highly similar, safe, and effective compared to existing approved biologics. This process involves advanced biotechnology, rigorous analytical testing, and clinical studies to demonstrate comparable quality, efficacy, and safety for regulatory approval. For instance, in February 2025, Biocon Biologics Limited, an India-based biopharmaceutical company, launched YESINTEK, a biosimilar designed to treat autoimmune diseases like Crohn’s disease, ulcerative colitis, and psoriasis, by targeting and inhibiting the activity of interleukin-12 and interleukin-23 to reduce inflammation and regulate the immune response. By mimicking the reference product stelara, Yesintek supports long-term disease management while simultaneously increasing patient access to biologic therapies.

Who Are The Leading Companies Driving The Autoimmune Monoclonal Antibody Market?

Major companies operating in the autoimmune monoclonal antibody market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., UCB S.A., Genmab A/S, Zymeworks Inc., Xencor Inc., Immutep Limited, Cue Biopharma Inc., Santa Ana Bio Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/autoimmune-monoclonal-antibody-global-market-report

Which Region Holds The Largest Share In The Autoimmune Monoclonal Antibody Market Today?

North America was the largest region in the autoimmune monoclonal antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autoimmune monoclonal antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=24162&type=smp

Browse Through More Reports Similar to the Global Autoimmune Monoclonal Antibody Market 2025, By The Business Research Company

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Granulocyte Colony Stimulating Factors Market 2025

https://www.thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market

Autoimmune Disease Diagnosis Market 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795